A Prospective Cohort Study of IgG4RD in China
ConditionIgG4-related Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorPeking Union Medical College Hospital
About this trial
This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Males and females
Age 18-75 years old with informed consent
swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions;
elevated serum IgG4 (>1.35 g/L)
Disqualifiers
Females planning to bear a child recently or with childbearing potential
Concurrent severe and/or uncontrolled and/or unstable diseases
Patient with malignancy
Trial population
Adult patients with newly diagnosed IgG4-related disease.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,000 Participants
are grouped into 1 trial groupGroup A: IgG4-RD
Trial outcomes
Primary outcomes
1
Clinical Response
Clinical Response is measured by IgG4-RD Responder Index, including organ/site score and serum IgG4 level.
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov